Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in NOMID / CINCA Syndrome
NCT00770601Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jan 2009
- Primary completion
- Feb 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of canakinumab in neonatal-onset multisystem inflammatory disease (NOMID), sponsored by Novartis. Started Jan 2009; status: terminated.
02
Drugs
canakinumab
03
Conditions
neonatal-onset multisystem inflammatory disease (NOMID)
Beyond the preview
Go deeper on NCT00770601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00770601.